IL175310A0 - Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists - Google Patents

Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists

Info

Publication number
IL175310A0
IL175310A0 IL175310A IL17531006A IL175310A0 IL 175310 A0 IL175310 A0 IL 175310A0 IL 175310 A IL175310 A IL 175310A IL 17531006 A IL17531006 A IL 17531006A IL 175310 A0 IL175310 A0 IL 175310A0
Authority
IL
Israel
Prior art keywords
ppar
activated receptor
peroxisome proliferator
derivatives useful
dual agonists
Prior art date
Application number
IL175310A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL175310A0 publication Critical patent/IL175310A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
IL175310A 2003-10-31 2006-04-27 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists IL175310A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51656103P 2003-10-31 2003-10-31
PCT/US2004/036028 WO2005041959A1 (en) 2003-10-31 2004-10-28 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists

Publications (1)

Publication Number Publication Date
IL175310A0 true IL175310A0 (en) 2006-09-05

Family

ID=34549548

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175310A IL175310A0 (en) 2003-10-31 2006-04-27 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists

Country Status (21)

Country Link
US (3) US7015329B2 (https=)
EP (1) EP1684752B1 (https=)
JP (1) JP2007527416A (https=)
KR (1) KR20060109925A (https=)
CN (1) CN1897939A (https=)
AR (1) AR046311A1 (https=)
AT (1) ATE362367T1 (https=)
AU (1) AU2004285530A1 (https=)
BR (1) BRPI0416106A (https=)
CA (1) CA2544317A1 (https=)
CR (1) CR8377A (https=)
DE (1) DE602004006529T2 (https=)
EA (1) EA009804B1 (https=)
EC (1) ECSP066536A (https=)
ES (1) ES2287786T3 (https=)
IL (1) IL175310A0 (https=)
NO (1) NO20062511L (https=)
TW (1) TW200528438A (https=)
UA (1) UA84035C2 (https=)
WO (1) WO2005041959A1 (https=)
ZA (1) ZA200604420B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
CN1897939A (zh) * 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体(ppar)双重激动剂的苯氧基乙酸衍生物
US20080045580A1 (en) * 2004-10-11 2008-02-21 Dr Reddy's Laboratories Limited Novel Isoxazole Compounds Having Ppar Agonist Activity
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
ES2399147T3 (es) 2006-09-08 2013-03-26 Rhode Island Hospital Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
RU2013114390A (ru) 2010-08-31 2014-10-10 СНУ Ар энд ДиБи ФАУНДЕЙШН Применение фетального репрограммирования посредством ppar-дельта-агониста
WO2012052412A1 (de) 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
CA2871640A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Par4 agonist peptides
LT2841437T (lt) 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2024153134A1 (zh) * 2023-01-18 2024-07-25 哈尔滨三联药业股份有限公司 五元杂环类化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6242493B1 (en) 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO1999065881A1 (en) 1998-06-19 1999-12-23 Nissan Chemical Industries, Ltd. Heterocyclic compounds as hypoglycemic agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
EP1177176B1 (en) 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Tri-aryl acid derivatives as ppar receptor ligands
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
DE60005973T2 (de) * 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
US6787552B2 (en) * 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
AU2003299790A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
CN1897939A (zh) * 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体(ppar)双重激动剂的苯氧基乙酸衍生物

Also Published As

Publication number Publication date
US20090131489A1 (en) 2009-05-21
ES2287786T3 (es) 2007-12-16
CR8377A (es) 2008-11-24
WO2005041959A1 (en) 2005-05-12
AU2004285530A1 (en) 2005-05-12
CN1897939A (zh) 2007-01-17
US7498351B2 (en) 2009-03-03
NO20062511L (no) 2006-07-27
EA009804B1 (ru) 2008-04-28
BRPI0416106A (pt) 2007-01-02
EP1684752B1 (en) 2007-05-16
ECSP066536A (es) 2006-12-20
AR046311A1 (es) 2005-11-30
US20050096362A1 (en) 2005-05-05
ZA200604420B (en) 2007-10-31
TW200528438A (en) 2005-09-01
JP2007527416A (ja) 2007-09-27
DE602004006529D1 (de) 2007-06-28
US7015329B2 (en) 2006-03-21
ATE362367T1 (de) 2007-06-15
KR20060109925A (ko) 2006-10-23
EP1684752A1 (en) 2006-08-02
CA2544317A1 (en) 2005-05-12
DE602004006529T2 (de) 2008-01-31
EA200600878A1 (ru) 2006-10-27
US20060074246A1 (en) 2006-04-06
UA84035C2 (ru) 2008-09-10

Similar Documents

Publication Publication Date Title
IL175310A0 (en) Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
IL162331A0 (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
PL376920A1 (pl) Podstawione pochodne 4-alkoksyoksazolu jako agoniści PPAR
IL175139A0 (en) Phenyl derivatives as ppar agonists
NO20032059D0 (no) Peroksisomprolferatoraktiverte reseptoralfa-agonister
DK1184366T3 (da) Substituerede phenylpropionsyrederivater som agonister for human perioxisomproliferatoraktiveret receptor alpha(PPAR)
SI2057122T1 (sl) Derivati 4-(2-amino-1-hidroksietil)fenola kot agonisti beta2-adrenergičnega receptorja
IL186150A0 (en) Novel thiophene derivatives as sphingosine-1-1phosphate-1 receptor agonists
IL173522A0 (en) Phenoxyacetic acid derivatives
GB0424729D0 (en) Probe end module for articulated arms
AU2003228485A1 (en) Farnesoid x-activated receptor agonists
PL2059513T3 (pl) Sposób wytwarzania pochodnych 1,2,4-oksadiazolowych kwasu benzoesowego
DK1735304T3 (da) Quinolinoncarboxamidforbindelser som 5-HT4-receptoragonister
IL161578A0 (en) Peroxisome proliferator activated receptor agonists
SI1924561T1 (sl) 6-arilalkilamino-2,3,4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja
AU775774C (en) Peroxisome proliferator-activated receptor agonist
WO2003028710A3 (de) Verbindungen zur reduzierung übermässiger nahrungsaufnahme
SI1551814T1 (sl) Derivati kiralne oksazol-arilpropionske kisline in njihova uporaba kot ppar-agonisti
AU2003261927A1 (en) Peroxisome proliferator-activated receptor controllers
ITRE20070020A1 (it) '' braccio snodato per la movimentazione di oggeti ''
ITVT20050003U1 (it) Gaffa/mezzomarina/gancio di accosto munito nella estremita' della impugnatura di vite/boccola/innesto
HK1071563A (en) Peroxisome proliferator activated receptor agonists
AU2003255893A1 (en) USE OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR $f(a)) AGONIST FOR THE TREATMENT OF CARNITINE PALMITOYL TRANSFERASE-2 DEFICIENCIES
PL114716U1 (en) Manipulator arm multi-shaft articulated joint
GB0519873D0 (en) PPAR Agonists I